Stock nose­dives for car­dio­vas­cu­lar drug­mak­er Ar­ca fol­low­ing Phase IIb AF fail­ure

A small bio­phar­ma near Den­ver is watch­ing its stock plunge fol­low­ing news that its Phase IIb heart drug was a bit of a bust. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.